Stay updated on Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial

Sign up to get notified when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The study on fenebrutinib for Primary Progressive Multiple Sclerosis (PPMS) has updated its participant enrollment numbers from approximately 946 to 985 and adjusted the number of study locations from 190 to 189. Additionally, the eligibility criteria for participants regarding liver disease have been clarified.
    Difference
    7%
    Check dated 2025-03-25T21:46:06.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.8%
    Check dated 2025-02-25T05:00:36.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.8%
    Check dated 2025-02-10T18:29:50.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The study has expanded to include 190 locations, adding several new hospitals and clinics across the United States, South America, Europe, and Asia, while removing 193 previous locations, including notable institutions in Connecticut, Florida, and various countries.
    Difference
    30%
    Check dated 2025-02-03T13:26:06.000Z thumbnail image
  8. Check
    67 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.0%
    Check dated 2025-01-20T05:13:22.000Z thumbnail image
  9. Check
    75 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in its functionality.
    Difference
    0.1%
    Check dated 2025-01-13T00:32:11.000Z thumbnail image

Stay in the know with updates to Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.